HIV-1 Envelope gp41 Broadly Neutralizing Antibodies: Hurdles for Vaccine Development

Open Access

Pearls Pearls provide concise, practical and educational insights into topics that span the pathogens field.

Laurent Verkoczy,

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Pathology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯
Garnett Kelsoe,

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯
Barton F. Haynes

* E-mail: Barton.haynes@duke.edu

Affiliations Duke Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America, Department of Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
⨯

Reader Comments (0)

HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
B cells
Is the Subject Area "B cells" applicable to this article?

Thanks for your feedback.
Antibodies
Is the Subject Area "Antibodies" applicable to this article?

Thanks for your feedback.
HIV vaccines
Is the Subject Area "HIV vaccines" applicable to this article?

Thanks for your feedback.
Antigens
Is the Subject Area "Antigens" applicable to this article?

Thanks for your feedback.
Vaccine development
Is the Subject Area "Vaccine development" applicable to this article?

Thanks for your feedback.
Immune response
Is the Subject Area "Immune response" applicable to this article?

Thanks for your feedback.
Immune tolerance
Is the Subject Area "Immune tolerance" applicable to this article?

Thanks for your feedback.